Introduction
============

In 1975, Georges Köhler and César Milstein described for the first time an experimental setup allowing for the cost-effective production of high quantities of antibodies exhibiting the same antigenic specificity.[@R1] This breakthrough discovery, which allowed Köhler and Milstein to win the 2004 Nobel Prize for Medicine or Physiology, de facto revolutionized an unbelievable number of research protocols and clinical applications.[@R2] During the past 30 years, the hybridoma technology originally described by Köhler and Milstein (which was purely murine and hence associated with relevant immunogenicity issues) has been consistently ameliorated, resulting in the production of ever more refined reagents for clinical applications.[@R3] In 1986, the US Food and Drud Administration (FDA) approved muromonab, a murine IgG1 specific for CD3, for the therapy of transplanted patients undergoing rejection.[@R4] Since then, dozens of monoclonal antibodies (mAbs), including murine, chimeric as well humanized reagents, have been approved by international regulatory agencies (including FDA and the European Medicines Agency, EMA) for use in humans against multiple diseases, including (but not limited to) autoimmune disorders and cancer.[@R2]^,^[@R5] Of these, no less than 14 mAbs, including naked reagents as well as mAbs coupled to antibiotics or radioactive isotopes, are nowadays authorized for use in cancer patients ([Table 1](#T1){ref-type="table"}).[@R5]^,^[@R6]

###### **Table 1.** Monoclonal antibodies currently approved for cancer therapy\*,\*\*

  -------------------------------------------------------------------------------------------------------------------------
  mAb                    Target   Approved   Type         Indication(s)
  ---------------------- -------- ---------- ------------ -----------------------------------------------------------------
  Alemtuzumab            CD52     2001       Hzed IgG1    Chronic lymphocytic leukemia

  Bevacizumab            VEGF     2004       Hzed IgG1    Glioblastoma multiforme, colorectal,\
                                                          renal and lung cancer

  Brentuximab\           CD30     2011       C IgG1       Hodgkin and anaplastic large cell\
  vedotin                                                 lymphoma (coupled to MMAE)

  Catumaxomab            CD3\     2009       M-R hybrid   Malignant ascites in patients\
                         EpCAM                            with EpCAM^+^ cancer

  Cetuximab              EGFR     2004       C IgG1       Head and neck and colorectal cancer

  Denosumab              RANKL    2011       H IgG2       Breast and prostate carcinoma

  Gemtuzumab             CD33     2000       Hzed IgG4    Acute myeloid leukemia\
                                                          (coupled with calicheamicin)

  Ibritumomab tiuxetan   CD20     2002       M IgG1       Non-Hodgkin lymphoma\
                                                          (coupled with ^90^Y or ^111^In)

  Ipilimumab             CTLA-4   2011       H IgG1       Melanoma

  Panitumumab            EGFR     2006       H IgG2       Colorectal carcinoma

  Ofatumumab             CD20     2009       H IgG1       Chronic lymphocytic leukemia

  Rituximab              CD20     1997       C IgG1       Chronic lymphocytic leukemia\
                                                          and non-Hodgkin lymphoma

  Tositumomab            CD20     2003       H IgG1       Non-Hodgkin lymphoma\
                                                          (naked or coupled with ^131^I)

  Trastuzumab            HER2     1998       Hzed IgG1    Breast carcinoma and gastric or gastresophageal junction cancer
  -------------------------------------------------------------------------------------------------------------------------

C, chimeric; CTLA-4, cytotoxic T lymphocyte antigen 4; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; H, human; Hzed, humanized; M, murine; mAb, monoclonal antibody; MMAE, monomethyl auristatin E; R, rat; RANKL, receptor activator of NFκB ligand; VEGF, vascular endothelial growth factor. \*By FDA or European Medicines Agency (EMA) at the day of submission. \*\*Updated from reference [@R6].

One year ago, concomitant with the launch of *OncoImmunology*, we published the first Trial Watch of what has then become a monthly series,[@R6]^-^[@R14] dealing with the use of mAbs in cancer therapy.[@R6] As described in details therein, mAbs that potentially exert antineoplastic effects belong to one of six, non-mutually exclusive classes: (1) mAbs that target cancer cell-intrinsic pro-survival signal transduction cascades (e.g., cetuximab, which inhibits the epidermal growth factor receptor, EGFR, and is currently employed for the therapy of colorectal cancer);[@R15] (2) mAbs that interrupt the trophic interaction between malignant cells and their stroma, hence indirectly inhibiting tumor growth (e.g., bevacizumab, which targets the vascular endothelial growth factor, VEGF, and is currently approved for use in patients affected by breast, lung, renal and colorectal carcinoma);[@R16] (3) mAbs that recognize antigens expressed on the surface of tumor cells and exert antineoplastic effects by engaging immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC),[@R5]^,^[@R17]^,^[@R18] antibody-dependent cellular phagocytosis (ADCP),[@R19] and complement-dependent cytotoxicity (CDC)[@R20]^,^[@R21] (e.g., rituximab, a naked anti-CD20 currently approved for use in lymphoma patients);[@R22]^-^[@R24] (4) trifunctional (bispecific) mAbs, which can bind two distinct antigenic targets while retaining the ability of activating immune effector functions (e.g., catumaxomab, an anti-CD3, anti-EpCAM chimeric mAb nowadays is use for the therapy of malignant ascites in patient with EpCAM^+^ neoplasms);[@R25] (5) immunoconjugates (e.g., ^90^Y-ibritumomab tiuxetan and ^131^I-tositumomab, two radionuclide-coupled anti-CD20 mAbs that are currently approved for the treatment of lymphoma patients);[@R26]^,^[@R27] and (6) immunostimulatory mAbs, i.e., mAbs that facilitate the development of an antitumor immune response by influencing the balance between the immunogenicity of malignant cells and the immunosuppressive mechanisms that they normally establish (e.g., ipilimumab, an anti-CTLA-4 mAb nowadays employed in melanoma patients).[@R28]^-^[@R31]

Here, we will summarize the latest developments in the clinical development of mAbs for cancer therapy, focusing on high impact studies that have been published during the last 15 months and clinical trials that have been launched in the same period to investigate the therapeutic profile of promising, yet hitherto experimental, mAbs. Of note, in this period, FDA has authorized one novel mAb for use in cancer patients and one oncological indication for a mAb that had previously been approved for the therapy of non-oncological patients (source <http://www.cancer.gov/cancertopics/druginfo>). Thus, brentuximab vedotin, an anti-CD30 monomethyl auristatin E (MMAE) conjugate, is now approved for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma patients,[@R32]^,^[@R33] In addition, denosumab, a receptor activator of NFκB ligand (RANKL)-targeting mAb that was employed in postmenopausal women at risk for osteoporosis, can nowadays be used to increase bone mass in patients who are at high risk of fracture as they undergo androgen deprivation therapy for non-metastatic prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.[@R34] Finally, the approval status of rituximab and cetuximab has recently been expanded in terms of therapeutic schedules and therapy-eligible patients subsets, respectively, while the authorization of bevacizumab as a therapeutic option for breast cancer patients has been revoked ([Table 1](#T1){ref-type="table"}).

Update on Clinical Reports
==========================

Since the submission of our previous Trial Watch on this topic (August 2011),[@R6] high-impact journals have published the results of no less than 50 clinical studies investigating the safety and efficacy of mAbs for cancer therapy. Obviously, a majority of these studies involved FDA-approved mAbs ([Table 1](#T1){ref-type="table"}), including bevacizumab (16 studies),[@R35]^-^[@R50] trastuzumab (11 studies),[@R46]^,^[@R51]^-^[@R60] rituximab (10 studies),[@R61]^-^[@R70] cetuximab (8 studies),[@R71]^-^[@R78] ipilimumab (4 studies),[@R79]^-^[@R82] alemtuzumab (2 studies),[@R83]^,^[@R84] and denosumab (1 study).[@R85] In addition, a few high-impact publications have reported on the clinical profile of experimental mAbs, including immunostimulatory anti-PD-1 and anti-PD-L1 mAbs,[@R86]^,^[@R87] the anti-CD22 calecheamicin conjugate inotuzumab ozogamicin,[@R88] the anti-CD19 maytansinoid conjugate SAR3419,[@R89] cixutumumab and figitumumab, two distinct mAbs specific for insulin-like growth factor 1 receptor (IGF1R),[@R90]^,^[@R91] pertuzumab, an anti-HER2 mAb,[@R92]^,^[@R93] and the CS1-targeting mAb elotuzumab.[@R94]^,^[@R95]

Thus, the clinical potential of FDA-approved mAbs, most often combined with conventional chemotherapeutic approaches, is under intensive investigation, an effort that will presumably lead to the approval of further oncological indications for these agents in the near future. In this respect, bevacizumab has been found to prolong progression-free survival (PFS) and overall survival (OS) in ovarian cancer patients treated with carboplatin and paclitaxel, in two randomized Phase III studies,[@R41]^,^[@R42] and to improve the rate of pathological complete responses (pCRs) among HER2-negative breast carcinoma patients undergoing neoadjuvant docetaxel-based chemotherapy, again in two large randomized Phase III trials.[@R44]^,^[@R45] The clinical profile of trastuzumab has most often been evaluated in cohorts of breast cancer patients,[@R46]^,^[@R51]^-^[@R58]^,^[@R60] reflecting the indications for which it has been authorized by FDA. In particular, two distinct, randomized Phase III studies demonstrated that the combination of neoadjuvant chemotherapy, trastuzumab and a chemical inhibitor of HER2, lapatinib, is clinically superior to use of either approach alone.[@R58]^,^[@R60] Similar to trastuzumab, rituximab has most extensively been tested in clinical settings that match its FDA-approved indications, i.e., cohorts of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) patients.[@R61]^-^[@R67] One notable exception to this trend is represented by the study of Kluin-Nelemans et al., demonstrating that rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone is efficient in old patients affected by mantle-cell lymphoma.[@R70] Cetuximab has been tested in a few different clinical settings, including cohorts of non-small cell lung carcinoma (NSCLC), pancreatic cancer and colorectal carcinoma patients.[@R71]^-^[@R78] Notably, EGFR expression levels have been shown to predict a survival benefit from the addition of cetuximab to first-line conventional chemotherapy in NSCLC patients.[@R74] Ipilimumab has been tested in cohorts of melanoma and NSCLC patients, alone or combined with paclitaxel and cisplatin, respectively,[@R81]^,^[@R82] as well as in prostate cancer patients undergoing vaccination,[@R79]^,^[@R80] invariably providing clinical benefits, at least to some extent. Finally, alemtuzumab and denosumab have been shown to improve the therapeutic potential of fludarabine in a cohort of CLL patients,[@R83] and to reduce the incidence of bone metastases in subjects affected by castration-resistant prostate carcinoma.[@R85]

Some experimental mAbs have also generated remarkable clinical results during the last 15 months. For instance, the mAb-mediated blockade of the interaction between the inhibitory receptor PD-1 (which is expressed by T cells) and its ligand (PD-L1), undertaken as a standalone intervention with either anti-PD-1 (MDX-1106, BMS-936558) or anti-PD-L1 (MDX-1105, BMS-936559) mAbs, has been shown to induce tumor regression or disease stabilization in a relatively small (but encouraging) proportion of patients affected by NSCLC, melanoma and renal cell carcinoma (RCC).[@R86]^,^[@R87] Inotuzumab ozogamicin has been associated with a promising therapeutic profile among refractory and relapsed acute lymphocytic leukemia patients.[@R88] The intravenous administration of SAR3419 to relapsed CD19^+^ B-cell lymphoma patients has been found to be safe and to elicit a consistent rate of clinical responses.[@R89] Along similar lines, anti-IGF1R mAbs such as cixutumumab and figitumumab have been shown to be well tolerated by children affected by refractory Ewing sarcoma, exhibiting modest antineoplastic activity as single agents.[@R90]^,^[@R91] The inclusion of pertuzumab in combinatorial regimens involving trastuzumab (alone or combined with docetaxel-based chemotherapy) have been associated with improved PFS (compared with the use of either mAb alone or chemotherapy plus trastuzumab only), in cohorts of HER2^+^ breast cancer patients.[@R92]^,^[@R93] Finally, in two distinct Phase I clinical trials, the combination of elotuzumab and bortezomib or lenalidomide plus low-dose dexamethasone was well tolerated and exhibited a promising efficacy in patients affected by relapsed or refractory multiple myeloma.[@R94]^,^[@R95]

Focusing on recent, high-impact mAb-related translational research, we have found of particular interest the studies by Yonesaka et al., Diaz et al. and Misale et al., demonstrating that colorectal carcinoma patients become refractory to EGFR-targeting mAbs including cetuximab and panitumumab along with the emergence of *KRAS* mutations or with an increased signaling via the EGFR-related receptor HER2;[@R96]^,^[@R97] as well as the work by Prahallad et al., revealing that---at least in a fraction of cases---the unresponsiveness of colon carcinoma patients to BRAF^V600E^ inhibitors stems from a feedback hyperactivation of EGFR signaling.[@R98]

Update on Investigational Monoclonal Antibodies under Clinical Evaluation
=========================================================================

When this Trial Watch was being redacted (October 2012), official sources listed 45 clinical trials launched after 2011, August 1 that would investigate the safety and therapeutic profile of hitherto investigational mAbs in cancer patients (source [www.clinicaltrials.gov](http://www.clinicaltrials.gov)).

*Bavituximab* is a chimeric IgG1 specific for phosphatidylserine (PS), an anionic phospholipid that---under physiological conditions---is found in the inner leaflet of the plasma membrane.[@R99] PS translocates to the cell surface in some instances of cell death,[@R100]^-^[@R102] cell activation and malignant transformation, and has been proposed to constitute a tumor vasculature-specific marker.[@R103]^,^[@R104] Encouraging preclinical findings by Ran et al.[@R99] supported the evaluation of bavituximab in clinical settings. Recent results from a Phase I study indicate that bavituximab at doses up to 3 mg/Kg/week is well tolerated by patients with advanced solid tumors.[@R105] Recently (since 2011, August 1), one single Phase I trial has been launched to assess the tolerability and preliminary therapeutic profile of bavituximab, combined with capecitabine and radiotherapy, in rectal adenocarcinoma patients (NCT01634685) ([Table 2](#T2){ref-type="table"}).

###### **Table 2.** Clinical trials recently launched to evaluate the therapeutic profile of monoclonal antibodies\*

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  mAb                                                         Target(s)                                 Indication(s)                     Phase                                  Status                   Note                                    Ref.
  ----------------------------------------------------------- ----------------------------------------- --------------------------------- -------------------------------------- ------------------------ --------------------------------------- -------------
  Bavituximab                                                 PS                                        Rectal carcinoma                  I                                      Recruiting               Combined with chemo- and radiotherapy   NCT01634685

  BC8                                                         CD45                                      Lymphoid tumors                   I                                      Not yet recruiting       Followed by ASCT                        NCT01678443

  Multiple myeloma                                            Recruiting                                Combined with fludarabine and\    NCT01503242                                                                                             
                                                                                                        TBI followed by transplantation                                                                                                           

  Blinatumomab                                                CD3\                                      B-precursor ALL                   I/II                                   Recruiting               As single agent                         NCT01471782
                                                              CD19                                                                                                                                                                                

  II                                                          NCT01466179                                                                                                                                                                         

  Ch14.18                                                     GD2                                       Neuroblastoma                     I/II                                   Recruiting               Combined with GM-CSF,\                  NCT01592045
                                                                                                                                                                                                          IL-2 and isotretinoin                   

  n.a.                                                        Not yet recruiting                        As single agent                   NCT01418495                                                                                             

  Cixutumumab                                                 IGF1R                                     Brain tumors\                     II                                     Recruiting               Combined with temsirolimus              NCT01614795
                                                                                                        Sarcoma                                                                                                                                   

  Melanoma                                                    Active, not recruiting                    As single agent                   NCT01413191                                                                                             

  Dalotuzumab                                                 IGF1R                                     Advanced solid tumors             I                                      Recruiting               As single agent or combined\            NCT01431547
                                                                                                                                                                                                          with ridaforolimus                      

  Breast cancer                                               II                                        Combined with exemestane\         NCT01605396                                                                                             
                                                                                                        and ridaforolimus                                                                                                                         

  Rectal cancer                                               Combined with irinotecan                  NCT01609231                                                                                                                               

  Ganitumab                                                   IGF1R                                     Advanced solid tumors             II                                     Recruiting               Combined with MEK inhibitors            NCT01562899

  Breast cancer                                               I/II                                      Withdrawn                         Combined with trastuzumab              NCT01479179                                                      

  Pancreatic cancer                                           I                                         Active, not recruiting            Combined with gemcitabine\             NCT01298401                                                      
                                                                                                                                          and followed by radiotherapy                                                                            

  I/II                                                        Completed                                 Combined with FOLFIRINOX          NCT01473303                                                                                             

  MDX-1105                                                    PD-L1                                     Hematological tumors              I                                      Withdrawn                As single agent                         NCT01452334

  MDX-1106                                                    PD-1                                      Advanced solid tumors             I                                      Recruiting               Combined with rIL-21                    NCT01629758

  Hematological tumors                                        As single agent                           NCT01592370                                                                                                                               

  HCC                                                         Not yet recruiting                        NCT01658878                                                                                                                               

  Melanoma                                                    NCT01621490                                                                                                                                                                         

  NSCLC                                                       III                                       Recruiting                        Combined with bevacizumab,\            NCT01454102                                                      
                                                                                                                                          erlotinib or chemotherapy                                                                               

  Not yet recruiting                                          As single agent                           NCT01642004                                                                                                                               

  NCT01673867                                                                                                                                                                                                                                     

  Renal cell carcinoma                                        I                                         Recruiting                        Combined with pazopanib or sunitinib   NCT01472081                                                      

  III                                                         Not yet recruiting                        As single agent                   NCT01668784                                                                                             

  Necitumumab                                                 EGFR                                      Advanced solid tumors             II                                     Recruiting               As single agent                         NCT01624467

  Solid tumors                                                Combined with cisplatin and gemcitabine   NCT01606748                                                                                                                               

  Nimotuzumab                                                 EGFR                                      Esophageal cancer                 II                                     Active, not recruiting   As single agent                         NCT01463605

  Recruiting                                                  Combined with FOLFIRI                     NCT01486992                                                                                                                               

  Combined with cisplatin and paclitaxel-based chemotherapy   NCT01688700                                                                                                                                                                         

  Head and neck cancer                                        Combined with 5-fluorouracil,\            NCT01425736                                                                                                                               
                                                              cisplatin and docetaxel                                                                                                                                                             

  Combined with radio- or chemotherapy                        NCT01516996                                                                                                                                                                         

  Combined with cisplatin\                                    NCT01616849                                                                                                                                                                         
  and 5-fluorouracil                                                                                                                                                                                                                              

  NSCLC                                                       II                                        Recruiting                        Combined with gefitinib                NCT01498562                                                      

  Ramucirumab                                                 VEGFR2                                    Breast cancer                     II                                     Recruiting               Combined with eribulin                  NCT01427933

  Solid tumors                                                I                                         Not yet recruiting                As single agent                        NCT01682135                                                      

  II                                                          Recruiting                                Combined with paclitaxel          NCT01515306                                                                                             

  Combined with docetaxel                                     NCT01567163                                                                                                                                                                         

  Not yet recruiting                                          Combined with FOLFIRI                     NCT01634555                                                                                                                               

  Siltuximab                                                  IL-6                                      Myelodysplastic syndrome          II                                     Active, not recruiting   Combined with best\                     NCT01513317
                                                                                                                                                                                                          supportive care                         

  Multiple myeloma                                            I/II                                      Recruiting                        Combined with bortezomib,\             NCT01531998                                                      
                                                                                                                                          dexamethasone and lenalidomide                                                                          

  II                                                          As single agent                           NCT01484275                                                                                                                               

  Tigatuzumab                                                 TRAILR2                                   Breast cancer                     II                                     Active, not recruiting   Combined with protein-\                 NCT01307891
                                                                                                                                                                                                          bound paclitaxel                        

  Tremelimumab                                                CTLA-4                                    Mesothelioma                      II                                     Active, not recruiting   As single agent                         NCT01649024

  Recruiting                                                  NCT01655888                                                                                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALL, acute lymphocytic leukemia; ASCT, autologous stem cell transplantation; CTLA-4, cytotoxic T lymphocyte antigen 4; EGFR, epidermal growth factor receptor; FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; FOLFIRINOX, 5-fluorouracil, leucovorin, irinotecan and oxaliplatin; IGF1R, insulin-like growth factor 1 receptor; GD2, ganglioside GD2; GM-CSF, granulocyte macrophage colony-stimulating factor; HCC, hepatocellular carcinoma; IL, interleukin; mAb, monoclonal antibody; MEK, MAPK/ERK kinase; n.a., not available; NSCLC, non-small cell lung carcinoma; rIL-21, recombinant interleukin-21; PD1, programmed cell death 1; PD-L1, PD1 ligand 1; PS, phosphatidylserine; TBI, total body irradiation; TRAILR2, tumor necrosis factor-related apoptosis-inducing ligand receptor 2; VEGFR2, vascular endothelial growth factor receptor 2. \*between 2011, August 1^st^ and the day of submission.

*BC8*, a CD45-targeting mAb that most often is conjugated to radionuclides (e.g., ^131^I, ^111^In), is currently under preclinical and clinical investigation for the treatment of CD45-expressing hematological malignancies.[@R106] The combination of BC8 with cyclophosphamide and total body irradiation (TBI) has previously been shown to be tolerated and convey clinical benefits in a small cohort of patients affected by myelodysplastic syndrome (MDS) and acute lymphoid leukemia (ALL).[@R107] Recently (since 2011, August 1), two Phase I trials have been launched to test the clinical profile of BC8, one involving multiple myeloma patients treated with BC8 in combination with fludarabine and TBI (NCT01503242), and one involving patients with refractory or relapsed lymphoid malignancies receiving BC8 as a standalone intervention (NCT01678443), in both cases as a pre-transplantation conditioning regimen ([Table 2](#T2){ref-type="table"}).

*Blinatumomab* belongs to the category of so-called BiTEs (bispecific T-cell engagers), i.e., bi-specific mAbs that invariably target CD3 (a component of the TCR signal transduction machinery expressed by T cells) and a tumor-associated antigen (in this case, CD19, a transmembrane protein mainly expressed by B cells).[@R108] Hence, unlike conventional monospecific mAbs, blinatumomab exerts antineoplastic effects by physically bridging malignant B cells and host T cells, hence promoting the cytotoxic activity of the latter.[@R108] High response rates and durable remissions have been observed in the first clinical trials testing the safety and therapeutic profile of blinatumomab among B-cell NHL and B-precursor ALL patients.[@R109]^-^[@R111] Recently (since 2011, August 1), two Phase I/II trials have been initiated to investigate the safety and efficacy of blinatumomab, given as a standalone intervention, in subjects affected by B-precursor ALL (NCT01466179, NCT01471782) ([Table 2](#T2){ref-type="table"}).

*Ch14.18* is a chimeric IgG1 specific for GD2, a disialoganglioside GD2 that is often abundant at the surface neuroendocrine tumor cells.[@R112]^,^[@R113] The evaluation of the safety and efficacy of Ch14.18 as a standalone agent for the treatment of melanoma and neuroblastoma has begun in the early 1990s,[@R114]^,^[@R115] with relatively unsatisfactory results. Later on, a few clinical studies have investigated the clinical potential of combinatorial regimens consisting of Ch14.18 in association with immunostimulatory cytokines like interleukin (IL)-2 and granulocyte macrophage-colony stimulating factor (GM-CSF) or metronomic chemotherapy,[@R116]^-^[@R119] reporting rather promising findings, in particular for the use of Ch14.18 in association with GM-CSF, IL-1 and isotretinoin (a retinoid) in high-risk neuroblastoma patients.[@R118] Recently (since 2011, August 1), two Phase I/II trials have been launched to test the therapeutic potential of Ch14.18, alone or combined with GM-CSF, IL-1 and isotretinoin, in neuroblastoma patients (NCT01418495; NCT01592045) ([Table 2](#T2){ref-type="table"}).

*Cixutumumab* (a fully human IgG1), *dalotuzumab* (a humanized IgG1) and *ganitumab* (a fully human IgG1) all target IGFR1, a transmembrane receptor that is overexpressed or hyperactivated by most, if not all, malignant tissues, hence operating as an anti-apoptotic signal transducer.[@R120] According to the results of early clinical trials, cixutumumab and dalotuzumab as single agents as well as the combination of cixutumumab and temsirolimus (an inhibitor of the intracellular signaling pathway elicited by IGFR1) are generally well tolerated by patients bearing advanced solid tumors,[@R91]^,^[@R121]^-^[@R123] with prominent adverse effects involving the dermis.[@R124] Conversely, dose-limiting toxicities have been reported to develop among unselected NSCLC patients treated with cixutumumab in combination with the EGFR inhibitor erlotinib at full dosage.[@R125] In 2012, results from 4 distinct clinical studies testing the safety and efficacy of ganitumab in patients affected by Ewing family tumors, pancreatic carcinoma or other solid malignancies have been published.[@R126]^-^[@R129] Globally, ganitumab---both as a single agent and associated with targeted agents or conventional chemotherapy---appears to be well tolerated and to exert antineoplastic activity, at least in a fraction of patients.[@R126]^-^[@R129] This said, results from less recent Phase III studies have shown that targeting the IGF1R pathway is not associated with clear clinical benefits in cancer patients.[@R130] Accordingly, several anti-IGF1R programs---including one large randomized Phase III study that originally aimed at testing the therapeutic potential of ganitumab among prostatic cancer patients (NCT01231347)---have lately been discontinued.[@R130]^,^[@R131] Recently (since 2011, August 1), two Phase II clinical trials have been launched to test the clinical profile of cixutumumab, either as a standalone intervention or combined with temsirolimus, in melanoma, sarcoma and brain cancer patients (NCT01413191; NCT01614795). In addition, three Phase I/II studies have been initiated to investigate the safety and efficacy of dalotuzumab, alone or in combination with ridaforolimus (a functional analog of temsirolimus) or conventional chemotherapeutics, in subjects bearing breast carcinoma, colorectal carcinoma or advanced solid tumors (NCT01431547; NCT01605396; NCT01609231). Finally, four Phase I/II studies have been initiated to assess the therapeutic potential of ganitumab, in combination with conventional chemotherapy, radiotherapy or trastuzumab, in individuals affected by breast carcinoma, pancreatic carcinoma or other advanced solid neoplasms (NCT01298401; NCT01473303; NCT01479179; NCT01562899). Of note, one of these studies (NCT01473303) is listed as complete, though results are not available, while another one (NCT01479179) has been withdrawn prior to patient enrollment, which somehow reflects current feelings about mAb-based anti-IGF1R cancer therapy ([Table 2](#T2){ref-type="table"}).

*MDX-1106* is a fully human IgG4 that specifically binds PD-1, a transmembrane receptor that---upon binding by its cognate ligand PD-L1, generates immunosuppressive signals in activated T cells.[@R132]^-^[@R134] In 2012, MDX-1106 (as well as of the PD-L1-targeting antibody *MDX-1105*) has been shown to be well tolerated and to induce objective clinical responses in a relatively small (but encouraging) proportion of patients affected by advanced NSCLC, melanoma and RCC.[@R86]^,^[@R87] Recently (since 2011, August 1), no less than 10 Phase I-III clinical trials have been launched to investigate the clinical potential of MDX-1105 and MDX-1106, given as standalone agents or combined with conventional chemotherapy (e.g., carboplatin + paclitaxel or cisplatin + gemcitabine or cisplatin + paclitaxel), targeted therapy (e.g., pazopanib or sunitinib, two tyrosine kinase receptor inhibitors) or immunostimulatory agents (e.g., recombinant IL-21), in cohorts of patients affected by hematological tumors (NCT01452334; NCT01592370), melanoma (NCT01621490), NSCLC (NCT01454102; NCT01642004; NCT01673867), hepatocellular carcinoma (NCT01658878), RCC (NCT01472081; NCT01668784), and advanced solid tumors (NCT01629758) ([Table 2](#T2){ref-type="table"}). Of note, the only study involving MDX-1105 (NCT01452334) has been withdrawn prior to patient enrollment, for undeclared reasons (source [www.clinicaltrials.gov](http://www.clinicaltrials.gov)).

Both *necitumumab* (a fully human IgG1) and *nimotuzumab* (a humanized IgG1) specifically bind EGFR, a transmembrane receptor with tyrosine kinase activity that is hyperactivated, due to point mutations, in a number of solid malignancies. Accordingly, a number of EGFR-targeting therapeutics have already been approved by FDA and other regulatory agencies for use in cancer patients, including the cell-permeant tyrosine kinase inhibitors erlotinib and gefinitib[@R135]^-^[@R137] and the anti-EGFR mAbs cetuximab and panitumumab ([Table 1](#T1){ref-type="table"}).[@R138]^,^[@R139] Still, the clinical interest in EGFR-targeting approaches is not decreasing, at least in part owing to the fact that most, if not all, FDA approved EGFR-targeting agents have been associated with the development of chemoresistance in a consistent fraction of patients.[@R96]^-^[@R98]^,^[@R140] The clinical development of nimotuzumab appears to be more advanced than that of necitumumab. Indeed, during the last 15 months, several pilot or Phase I studies investigating the safety and preliminary therapeutic profile of nimotuzumab (given as a standalone intervention or combined with standard radio- or chemotherapeutic regimens) in patients affected by various solid malignancies have been concluded, overall reporting a low incidence of tolerable adverse effects and improved disease outcome, at least in a fraction of cases.[@R141]^-^[@R154] Conversely, no reports have been published since 2010 on the clinical profile of necitumumab.[@R144] Recently (since 2011, August 1), a total of 9 Phase II clinical trials have been initiated to investigate the safety and efficacy of necitumumab (NCT01606748; NCT01624467) or nimotuzumab (NCT01425736; NCT01463605; NCT01486992; NCT01498562; NCT01516996; NCT01616849; NCT01688700), as single agents or associated with standard chemotherapy, in cohorts of head and neck cancer (NCT01425736, NCT01516996; NCT01616849) esophageal cancer (NCT01463605; NCT01486992; NCT01688700) and NSCLC (NCT01498562) patients, as well as of individuals affected by various solid tumors (NCT01606748; NCT01624467) ([Table 2](#T2){ref-type="table"}).

*Ramucirumab* (IMC-1121B) is a fully human IgG1 specific for the VEGF receptor 2 (VEGFR2). By antagonizing endogenous VEGF signaling,[@R155] ramucirumab inhibits of the most prominent interactions between neoplastic and stromal cells, i.e., neo-angiogenesis.[@R156] Early Phase I clinical trials demonstrated that ramucirumab is generally well tolerated by cancer patients,[@R155]^,^[@R157] and prompted the launch of a randomized, double-blind Phase III study to evaluate whether ramucirumab can improve the efficacy of docetaxel-based chemotherapy in subjects bearing stage IV NSCLC (NCT01168973, registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) on July 2010).[@R158] This study has not yet been concluded. More recently (since 2011, August 1), 5 distinct Phase I clinical trials have been commenced to investigate the tolerability and efficacy of ramucirumab, most often combined with conventional chemotherapeutics, in subjects affected by breast carcinoma (NCT01427933) or other solid neoplasms (NCT01515306; NCT01567163; NCT01634555; NCT01682135) ([Table 2](#T2){ref-type="table"}).

*Siltuximab* (CNTO-328) is a chimeric IgG1 that binds to IL-6, a pleiotropic cytokine that reportedly modulates several aspects of oncogenesis and tumor progression, including the balance between cell proliferation and cell death as well as neo-angiogenesis.[@R159] Siltuximab-based monotherapy as well as combinatorial regimens including siltuximab and mitoxantrone + prednisone or siltuximab + docetaxel have lately been reported to be well tolerated by prostate cancer patients, although objective effects on disease outcome could not always be documented.[@R160]^-^[@R162] Since 2011, August 1, 3 Phase I/II clinical trials have been launched to assess the therapeutic profile of siltuximab, as a single agent or combined with best supportive care or bortezomib + dexamethasone + lenalidomide, in MDS (NCT01513317) and multiple myeloma (NCT01484275; NCT01531998) patients ([Table 2](#T2){ref-type="table"}). Conversely, the Phase III trial NCT01266811, which was initiated in December 2010 to test the efficacy of siltuximab + bortezomib + dexamethasone in similar patient cohorts has been withdrawn prior to patient enrollment for undeclared reasons (source [www.clinicaltrials.gov](http://www.clinicaltrials.gov)).

*Tigatuzumab* (CS-1008) is a humanized IgG1 that functions as an agonist for tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAILR2), hence promoting the death of TRAILR2-expressing malignant (but not non-transformed) cells.[@R163] Although the molecular basis underlying the selectivity of tigatuzumab remains unclear,[@R164]^,^[@R165] the results of preliminary Phase I-II studies in cancer patients were encouraging, suggesting that tigatuzumab is generally well tolerated.[@R166] Recently (since 2011, August 1), 1 Phase II clinical trial has been initiated to test the safety and efficacy of tigatuzumab combined with abraxane (protein-bound paclitaxel particles), in breast carcinoma patients (NCT01307891) ([Table 2](#T2){ref-type="table"}).

*Tremelimumab* (ticilimumab, CP-675,206) is a human IgG2 that, similar to the FDA-approved mAb ipilimumab, inhibits the development of peripheral tolerance by antagonizing the immunosuppressive receptor CTLA-4 on the surface of T cells.[@R167]^,^[@R168] Combinatorial regimens including tremelimumab + high-dose interferon α-2b (IFNα-2b) and tremelimumab + androgen deprivation have recently been shown to be well tolerated by melanoma and prostate carcinoma patients,[@R169]^,^[@R170] respectively. Since 2011, August 1, 2 Phase II studies have been launched to investigate the clinical profile of tremelimumab, invariably employed as a standalone intervention, in mesothelioma patients (NCT01649024; NCT01655888) ([Table 2](#T2){ref-type="table"}).

Concluding Remarks
==================

In no more than 15 months, besides extending the indications of mAbs that were previously approved in oncological settings, the US FSA has authorized the use in cancer patients of two novel mAbs, brentuximab vedotin and denosumab.[@R32]^-^[@R34] In the very same period, (1) results from no less than 50 clinical studies testing the safety and antineoplastic profile of mAbs have been published in top-impact forums; and (2) approximately 50 novel mAb-based clinical trials enrolling cohorts of cancer patients have been registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Thus, the interest in the clinical development of mAbs for cancer therapy remains very high.

With two notable exceptions (i.e., NCT01266811 and NCT01231347), all Phase III studies that we listed in our latest Trial Watch dealing with mAbs and cancer therapy are still ongoing.[@R6] The results of these large, randomized clinical trials are likely to determine whether novel mAbs will soon be authorized by FDA and/or other international regulatory agencies for use in cancer patients. In addition, an intense wave of preclinical investigation is ongoing not only to discover novel mAb-druggable oncology-relevant targets, but also to generate further insights into the molecular and cellular circuitries whereby mAbs actually exert antineoplastic effects and how this knowledge can be translated into more stable and more efficient therapeutics.[@R6]^,^[@R29]^,^[@R171] In the mid-long term, such preclinical studies will surely generate the next generation of mAbs for clinical development.

No potential conflicts of interest were disclosed.

Authors are supported by the Ligue contre le Cancer (équipes labelisées), AXA Chair for Longevity Research, Cancéropôle Ile-de-France, Institut National du Cancer (INCa), Fondation Bettencourt-Schueller, Fondation de France, Fondation pour la Recherche Médicale, Agence National de la Recherche, the European Commission (Apo-Sys, ArtForce, ChemoRes. Death-Train) and the LabEx Immuno-Oncology.

Previously published online: [www.landesbioscience.com/journals/oncoimmunology/article/22789](http://www.landesbioscience.com/journals/oncoimmunology/article/22789/)

ADCC

:   antibody-dependent cellular cytotoxicity

ADCP

:   antibody-dependent cellular phagocytosis

ALL

:   acute lymphoid leukemia

BiTE

:   bispecific T-cell engager

CDC

:   complement-dependent cytotoxicity

CLL

:   chronic lymphocytic leukemia

FDA

:   Food and Drug Administration

EGFR

:   epidermal growth factor receptor

EMA

:   European Medicines Agency

GM-CSF

:   granulocyte macrophage-colony stimulating factor

IFNα-2b

:   interferon α-2b

IGF1R

:   insulin-like growth factor 1 receptor

IL

:   interleukin

mAb

:   monoclonal antibody

MMAE

:   monomethyl auristatin E

MDS

:   myelodysplastic syndrome

NHL

:   non-Hodgkin lymphoma

NSCLC

:   non-small cell lung carcinoma

OS

:   overall survival

pCR

:   pathological complete response

PFS

:   progression-free survival

PS

:   phosphatidylserine

RANKL

:   receptor activator of NFκB ligand

TRAILR2

:   tumor necrosis factor-related apoptosis-inducing ligand receptor 2

TBI

:   total body irradiation

VEGF

:   vascular endothelial growth factor

VEGFR2

:   VEGF receptor 2
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